MARKET

KROS

KROS

Keros Therapeutics, Inc.
NASDAQ
21.69
+1.42
+7.01%
After Hours: 21.90 +0.21 +0.97% 19:59 12/05 EST
OPEN
20.26
PREV CLOSE
20.27
HIGH
21.93
LOW
20.26
VOLUME
1.12M
TURNOVER
--
52 WEEK HIGH
72.37
52 WEEK LOW
9.12
MARKET CAP
660.81M
P/E (TTM)
14.05
1D
5D
1M
3M
1Y
5Y
1D
Largest borrow rate increases among liquid names
TipRanks · 1d ago
Weekly Report: what happened at KROS last week (1124-1128)?
Weekly Report · 5d ago
Keros Therapeutics Price Target Raised to $19.00/Share From $18.00 by B of A Securities
Dow Jones · 11/28 17:17
Keros Therapeutics Is Maintained at Neutral by B of A Securities
Dow Jones · 11/28 17:17
B of A Securities Maintains Neutral on Keros Therapeutics, Raises Price Target to $19
Benzinga · 11/28 17:08
Buy These 5 Best Value Stocks to Make the Most of P/B Ratio
NASDAQ · 11/28 14:53
Keros Therapeutics (KROS) Gets a Hold from Bank of America Securities
TipRanks · 11/28 13:55
Keros Therapeutics price target raised to $19 from $18 at BofA
TipRanks · 11/28 13:40
More
About KROS
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.

Webull offers Keros Therapeutics Inc stock information, including NASDAQ: KROS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KROS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KROS stock methods without spending real money on the virtual paper trading platform.